Asia Pacific AIDS & Co-infections Conference 2018 chlamydia

Daisuke Mizushima

This was an oral presentation and a poster of the same research about testing the cure rates of Azithromycin 1g used for treating anal Chlamydia in HIV positive and negative MSM in Japan. Daisuke acknowledged that previous studies had showed a high failure rate using Azithromycin to treat anal Chlamydia. The following slides describe the study undertaken in Japan:

I noted a poster on treatment of anorectal chlamydia in MSM in Japan (Mizushima D et al). In Australia, the use of single dose of azithromycin  is questioned based on retrospective studies of its effectiveness. This prospective study followed 125 MSM with and without HIV with transcription mediated amplication confirmed anal chlamydia. They were all given AZM 1gm as a  single dose and then a test of cure at 3 weeks. If they failed the test of cure they were given Doxy 200mg daily for a week and tested again 3 weeks later. Of the 118  MSM treated (7 dropped out) 87% were cured by AZM. Of the the 15 who failed to AZM treatment 12 were treated  (3 dropped out) with Doxy and they were all cured.

There was no difference in effectiveness of AZM between HIV infected (97) and not HIV infected  (21) in responding to AZM